The natural history of multiple sclerosis: a geographically based study. 4. Applications to planning and interpretation of clinical therapeutic trials.
about
The Multiple Sclerosis Functional Composite: a new clinical outcome measure for multiple sclerosis trialsCNS immune privilege: hiding in plain sight.Pharmacological Approaches to Delaying Disability Progression in Patients with Multiple SclerosisNatural history of primary progressive multiple sclerosisPossible clinical outcome measures for clinical trials in patients with multiple sclerosisThe role of MRI in the evaluation of secondary progressive multiple sclerosis.Outcome Measures in Clinical Trials for Multiple Sclerosis.Physicians, subsequence and consequence.Multivariate analysis of predictive factors of multiple sclerosis course with a validated method to assess clinical eventsCerebellar Dysfunction in Multiple Sclerosis.Does a placebo-effect exist in clinical trials on multiple sclerosis? Review of the literature.Aggressive multiple sclerosis: proposed definition and treatment algorithm.Immunological aspects of secondary progressive multiple sclerosis.Microglia as liaisons between the immune and central nervous systems: functional implications for multiple sclerosis.Randomised, double blind, placebo controlled study of interferon beta-1a in relapsing-remitting multiple sclerosis analysed by area under disability/time curvesTreatment of multiple sclerosis with interferon beta: an appraisal of cost-effectiveness and quality of life.Disability outcome measures in therapeutic trials of relapsing-remitting multiple sclerosis: effects of heterogeneity of disease course in placebo cohorts.One year changes in disability in multiple sclerosis: neurological examination compared with patient self reportEvoked potential studies in the antiphospholipid syndrome: differential diagnosis from multiple sclerosis.Prognosis of multiple sclerosis: clinical factors predicting the late evolution for an early treatment decision.Investigation of relationship between social capital and quality of life in multiple sclerosis patients.Review of the clinical evidence for interferon beta 1a (Rebif) in the treatment of multiple sclerosisImmunotherapy for multiple sclerosis.Treatment trials in progressive MS--current challenges and future directions.The challenges of measuring disability accumulation in relapsing-remitting multiple sclerosis: evidence from interferon beta treatments.Age Related Multiple Sclerosis Severity Score: Disability ranked by age.Approved Beta interferons in relapsing-remitting multiple sclerosis: is there an odd one out?Features of anti-aquaporin 4 antibody-seropositive Chinese patients with neuromyelitis optica spectrum optic neuritis.Comparative evaluations of neuroperformance and clinical outcome assessments in chronic progressive multiple sclerosis: I. Reliability, validity and sensitivity to disease progression. Multiple Sclerosis Study Group.Multiple sclerosis: from molecules to treatment.The natural history of multiple sclerosis: a geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis.Cortical plasticity predicts recovery from relapse in multiple sclerosis.Prospective study of multiple sclerosis with early onset.Corpus callosum damage predicts disability progression and cognitive dysfunction in primary-progressive MS after five years.Evidence of treatment benefit: is seeing believing or obfuscation by statistics?The natural history of multiple sclerosis: a geographically based study. 7. Progressive-relapsing and relapsing-progressive multiple sclerosis: a re-evaluation.Temporal course of upregulation of Na(v)1.8 in Purkinje neurons parallels the progression of clinical deficit in experimental allergic encephalomyelitis.Prediction of natalizumab anti-drug antibodies persistency.A feasibility study to investigate the effect of functional electrical stimulation and physiotherapy exercise on the quality of gait of people with multiple sclerosis.Long-term emotional state of multiple sclerosis patients treated with interferon beta.
P2860
Q22241715-63661EDA-E5EC-4142-A718-A2FD1527C4B3Q24642697-CDE66E67-F398-4857-915D-F8E40733331DQ27000269-AC7DB6CB-4130-4FA7-B83D-DC148FA8BF15Q29391465-0E5518BF-20DA-409C-B20F-D489DB322EA0Q30433837-5A7B193B-3F61-4A0E-BD79-81F0E15AA7EBQ31033345-C817E81E-AFF4-41B5-BAA5-EEA5A18753B9Q31160866-AD9D3B79-7E8E-47AC-B98A-53464D9109C5Q33712704-CA83C779-11DB-4A73-B1BF-9C78E8EAA9CAQ33733828-D80FDE4E-1C38-4E59-A9A9-0E769420C2E3Q33843083-DB4B3901-6CA8-4FC6-A99E-12A10B9C4AC8Q34396068-0392CFB7-B874-4034-BD98-7E0A884EC3C5Q34478828-0F8F7AA3-A1A3-4791-A4F0-AEAB7A946FB7Q34590324-2755E7DC-4505-4768-9933-EDEDB1A77E99Q34963755-280951D3-6611-461D-B575-D0D8B0EF5EE7Q35453326-44F6B0C2-5357-45E8-9414-72FE3562B426Q35455334-1DA04CE2-AF89-4F1F-9B0C-00828330A7FBQ35456042-44B7740A-7E90-4145-AFA0-DD05F41F9EFFQ35472473-FF89B87F-9C7F-4EFF-A2C6-E22FBADF74B5Q35636977-1351E1A4-EC43-49A8-A25A-23A77BA1334AQ36419573-BD735C9D-D0E5-4A46-AAC7-49FED86D2970Q36780532-24A53E6D-3C5E-477D-BB87-3FDE5CBE51F2Q36842201-3724DEA2-49F2-4713-9760-C6C7FFA2EA9BQ36850073-62E301C9-3A65-4C3A-BFC0-017CF3DF1881Q38125123-18DE05D3-E226-4974-A132-7DF30B32EB8FQ38177871-F836D323-8E3A-424E-B8DB-E88414468918Q38982429-B6FFE9DC-9C26-44EC-8815-C6354C04A305Q39671084-C6ABF3F2-1CAA-48DA-8AF9-8080EFE6892DQ40750306-C12B098F-DBE1-46C8-BAC0-3EFF230ED1F9Q40923758-3BA8FF72-271F-4FB0-9C5E-94A873A52558Q43138599-59659C83-739A-4EEA-8B10-B1A38FD4A94AQ43462704-309A8663-6B56-4824-9F71-B506B1A6EDC4Q43524630-BB31B694-4D92-40BA-A716-F497AA79332BQ43980182-D63F1107-0409-4E4D-B838-5FB17354E6D6Q45901843-A469B4F6-C5D2-4C1E-BF63-89710CEF25FEQ46622255-B6848536-48F5-4704-93EA-919E0CA282B2Q48101206-EEDDCB47-B58A-4833-8774-432DC556F416Q48177322-029C9740-75C7-46A8-9F71-2502D9718807Q48237799-34EAEC56-2139-4873-A016-DE1469E117D2Q48961533-A6BDEBA2-A064-4E6D-9A79-F90159D2CE5EQ50911460-6C13321D-0BE0-4370-A81B-522805B1D8EC
P2860
The natural history of multiple sclerosis: a geographically based study. 4. Applications to planning and interpretation of clinical therapeutic trials.
description
1991 nî lūn-bûn
@nan
1991年の論文
@ja
1991年論文
@yue
1991年論文
@zh-hant
1991年論文
@zh-hk
1991年論文
@zh-mo
1991年論文
@zh-tw
1991年论文
@wuu
1991年论文
@zh
1991年论文
@zh-cn
name
The natural history of multipl ...... f clinical therapeutic trials.
@en
type
label
The natural history of multipl ...... f clinical therapeutic trials.
@en
prefLabel
The natural history of multipl ...... f clinical therapeutic trials.
@en
P2093
P356
P1433
P1476
The natural history of multipl ...... f clinical therapeutic trials.
@en
P2093
Baskerville J
Carriere W
Noseworthy JH
Weinshenker BG
P304
P356
10.1093/BRAIN/114.2.1057
P407
P478
114 ( Pt 2)
P577
1991-04-01T00:00:00Z